Novotech CRO Attracts Investment for Asia Clinical Trial Expansion
Novotech
, Australia’s largest independent CRO today announced a funding injection from private equity firm
Mercury Capital
.
Novotech CEO Alek Safarian said, “Novotech is focused on the fast-growing Asia region. We are already active in 10 countries in the region on behalf of our biotechnology and pharmaceutical clients. This investment will further accelerate our expansion plans.”
“Novotech works predominantly with U.S. and EU pharmaceutical and biotech companies and is currently managing around 70 trials across a wide range of therapeutic areas including oncology and cardiovascular disease.”
Mercury Capital acquired a 30% stake in Novotech and has the option to increase this to 50% at a later date. Mercury Capital was founded by former Goldman Sachs managing director Clark Perkins, and typically invests in firms with an enterprise value between $30-120M.
“We’re excited by the organic growth opportunities in Australia and Asia, and acquisition opportunities in the latter,” Mr. Perkins told The Wall Street Journal MoneyBeat in a recent interview.
“There’s a strong trend of major pharmaceutical companies outsourcing, which has led to underlying annual compound growth in the market of between 5% and 10%,” Mr. Perkins said. “Novotech is growing much faster than this,” he added.
Novotech, a leading regional full service CRO headquartered in Australia with offices in New Zealand, Singapore, India, Malaysia, Thailand, Taiwan and South Korea, has been instrumental in the success of hundreds of phase I-IV clinical trials.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
